New HIV Vaccine DevelopmentOpportunity to explore collaboration for the development of an HIV vaccine candidate leveraging Aridis Pharmaceuticals' broadly neutralizing antibody platform, presenting a potential sales avenue to offer support in this groundbreaking initiative.
Investment from CFFWith a significant investment of $4.85 million from the Cystic Fibrosis Foundation, Aridis Pharmaceuticals is actively advancing AR-501 nebulized gallium citrate for treating chronic lung infections, highlighting an area where sales strategies can align with ongoing funding and research efforts.
Grant for Inhaled Formulation TechnologyThe $1.9 million grant received from the Gates Foundation for evaluating inhaled formulation technology to deliver monoclonal antibodies against influenza and SARS-CoV-2 signifies a focus on global healthcare solutions, offering a potential sales opportunity in supporting this innovative approach.
Strategic Partnership with UAB and Texas BiomedCollaboration with partners like UAB and Texas Biomed to develop inhaled antibody treatments presents a strategic avenue for sales expansion, tapping into the momentum of successful antibody candidates deployment akin to asthma inhalers.
Exclusive Licensing Agreement with AstraZenecaThe exclusive worldwide licensing agreement with AstraZeneca for suvratoxumab, a late-stage monoclonal antibody candidate, opens up avenues for sales collaboration and business development in the realm of advanced anti-infectives, marking a significant opportunity for revenue growth.
Aridis Pharmaceuticals uses 8 technology products and services including Matomo, WordPress Super Cache, Sucuri, and more. Explore Aridis Pharmaceuticals's tech stack below.
| Aridis Pharmaceuticals Email Formats | Percentage |
| LastF@aridispharma.com | 81% |
| First.Last@aridispharma.com | 8% |
| FirstL@aridispharma.com | 8% |
| First@aridispharma.com | 3% |
Biotechnology ResearchCalifornia, United States11-50 Employees
Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR).
Company Overview
Media & News
Funding & FinancialsAridis Pharmaceuticals has raised a total of $2.3M of funding over 12 rounds. Their latest funding round was raised on Mar 14, 2023 in the amount of $2.3M.
Aridis Pharmaceuticals's revenue is in the range of $10M
Funding & FinancialsAridis Pharmaceuticals has raised a total of $2.3M of funding over 12 rounds. Their latest funding round was raised on Mar 14, 2023 in the amount of $2.3M.
Aridis Pharmaceuticals's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com